浏览网站：三诺血糖仪官方网站
联系电话：400 887 0036
公司地址： 长沙市国家高新技术开发区谷苑路265号
三诺生物简介
About Sinocare Inc.
三诺生物传感股份有限公司是一家致力于利用生物传感技术研发、生产、销售快速检测慢性疾病产品的高新技术企业。自2002年创立以来，一直秉承“恪守承诺、奉献健康”的企业宗旨，专注于推动糖尿病健康事业的发展。
Sinocare Inc. is a high-tech company. We have been fully dedicated to the innovation of biosensor technology, developing, manufacturing and marketing rapid diagnosis testing products for people with chronic diseases and healthcare professionals. By cherishing our core values of “Honor the Commitment, Dedicate to Healthcare”, Sinocare has been working on promotion the development of diabetic healthcare industry, since our establishment in 2002.
三诺生物麓谷生物传感器产业基地位于长沙国家高新技术产业开发区，建筑面积66000㎡，是亚洲最大的血糖仪及试条生产基地。
Sinocare Lu Valley Biosensor Manufacturing Facility located in Changsha National High-Tech Industrial Development Zone was launched in 2013. With around 66,000 m2 gross area, our factory becomes the biggest Blood Glucose Monitoring System (BGMS) production base in Asia.
三诺作为国家生物医学工程高技术产业化示范项目，多次获得国家创新基金支持，并率先通过了ISO 13485质量管理体系认证及欧盟CE认证。公司生产的“三诺”系列血糖仪及配套试纸，以其“准确、简单、经济”的特点，获得广大消费者的认可，“三诺”被中国工商总局认定为“中国驰名商标”。
As one of the demonstration projects of National Biomedical Engineering High-Tech Industrialization Program, Sinocare received financial supports from the National Innovation Fund for several times, and passed ISO: 13485 quality management system certification and European CE certificate in 2007. The high-quality BGMS sold under “SANNUO” brand has won the recognition from various consumers because of its accuracy, simplicity and affordability. The trademark “SANNUO/三诺” has been recognized and accredited as the “well-known trademark in China” by SAIC (State Administration for Industry and Commerce), which is the highest honor for the Chinese brands.
公司产品不仅畅销国内，且大规模出口国际市场。
Sinocare products are not only best-selling in the domestic market, and have also been successfully exported to the international market.
2012年3月19日，公司在深圳证券交易所创业板上市，成为全国生物传感器上市第一股。
On March 19th of 2012, Sinocare was listed on the Growth Enterprise Market of SZSE (Shenzhen Stock Exchange SHE: 300298) and became the first biosensor stock in China.
2015年公司血糖仪在国内零售市场的份额达到51%，成为我国血糖监测产品行业领导者，同年入选了“福布斯亚洲中小上市企业200强”榜单。
By gaining over 51% market share of domestic BGMS in retail channel, Sinocare has become the leader in BGMS industry of China by 2015, then it has been listed by Forbes as one of Asia's 200 Best Under a Billion companies.
2014年9月，三诺收购北京健恒糖尿病医院；
In September of 2014, Sinocare acquired Beijing Sannuo Jianheng Diabetes Clinic.
2016年1月，收购美国Trividia Health Inc.（原美国尼普洛诊断有限公司），成为全球第六大血糖仪企业，迈入全球血糖仪领先阵营。
By completing the acquisition of Nipro Diagnostics (renamed Trividia Health Inc.), a leading developer, manufacturer and marketer of advanced performance products for people with diabetes, in January of 2016, Sinocare has become the 6th largest BGMS supplier among the rank top 10 in the global market.
2016年7月，收购美国PTS，积极拓展poct检测业务，为慢病防治提供更全面的解决方案。
In July of 2016, Sinocare acquired PTS Diagnostics, a US-based manufacturer of point-of-care biometric testing devices.
With Trividia and PTS, together, Sinocare will provide an integrated healthcare solution for the people with chronic diseases.
遵循“平等、诚信、创新、卓越”的价值观，三诺生物持续创新，践行从“血糖仪普及推动者”向“全球血糖仪专家”战略转型，直至实现“糖尿病慢病健康服务专家”的战略愿景。为慢性疾病的防治提供更多创新性、系统性的智慧医疗解决方案，提高糖尿病等慢性疾病患者的生活质量。
By embracing the shared values of equality, integrity, innovation and excellence, Sinocare will continue to build the sustainable innovation-driven platform, speed up the process of strategic shift from “the BGMS Promoter in China” to “the BGMS Expert in the World”, and achieve our ultimate goal of “the Diabetes Management Expert”. We will continue to provide more innovative and systematic smart healthcare solutions to fight chronic diseases. We will help people with diabetes, heart disease and other chronic diseases to live better and healthier lives.
